ABOUT US
CARA Yakhteh Tajhiz Azma Co. was established in 2018 with a focus on producing a CAR-T CELL therapy product, a CD19 directed genetically modified autologous T cell immunotherapy for the treatment of relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL) and Lymphoma. CARA Yakhteh Tajhiz Azma Co. is the first company in Iran to have developed CAR-T CELL therapy.
WHO WE ARE?
- At CARA Yakhteh, we are advancing the frontier of autologous CAR T-cell therapy through cutting-edge cellular reprogramming. Our mission is to develop highly targeted, patient-specific treatments that offer new hope for those battling cancer. By integrating research, development, and manufacturing under one roof, we’re shaping a new era of precision immunotherapy—where science meets impact.
- CARA Yakhteh is dedicated to creating powerful new treatments that use your own immune cells to fight cancer. Our scientists work to turn T cells into smart, targeted therapies designed just for you. We believe every patient deserves a personalized approach, and we’re building the tools to make that possible—bringing hope, healing, and innovation together.
WHERE TO FIND US?
Central office
Biotechnology Development center building, National Research Institute of Genetic Engineering, Pajouhesh Blvd, Hamedani HWY, Tehran, Iran
Factory
Comprehensive Research Laboratory Building, No. 41, Italy St, vesal shirazi St, Tehran, iran